Routine cerebral embolic protection during transcatheter aortic-valve implantation
Routine cerebral embolic protection during transcatheter aortic-valve implantation
Background: transcatheter aortic-valve implantation (TAVI) is associated with procedure-related stroke. Cerebral embolic protection (CEP) devices may reduce embolization to the cerebral circulation and hence the incidence of stroke.
Methods: we conducted a randomized, controlled trial across 33 centers in the United Kingdom. We randomly assigned 7635 participants with aortic stenosis in a 1:1 ratio to undergo TAVI with a CEP device (CEP group) or TAVI without a CEP device (control group). The primary outcome was stroke within 72 hours after TAVI or before discharge from the hospital (if discharge occurred sooner).
Results: a total of 3815 participants were assigned to the CEP group and 3820 to the control group. A primary-outcome event occurred in 81 of 3795 participants (2.1%) in the CEP group and in 82 of 3799 participants (2.2%) in the control group (difference, −0.02 percentage points; 95% confidence interval, –0.68 to 0.63; P=0.94). Disabling stroke occurred in 47 participants (1.2%) in the CEP group and in 53 (1.4%) in the control group. Death occurred in 29 participants (0.8%) in the CEP group and in 26 (0.7%) in the control group. Overall access-site complications appeared to be similar in the two groups (8.1% in the CEP group and 7.7% in the control group). A total of 24 serious adverse events occurred in 22 of 3798 participants (0.6%) in the CEP group, and 13 serious adverse events occurred in 13 of 3803 participants (0.3%) in the control group.
Conclusions: among participants undergoing TAVI, routine use of CEP did not decrease the incidence of stroke within 72 hours. (Funded by the British Heart Foundation and Boston Scientific; BHF PROTECT-TAVI ISRCTN Registry number, ISRCTN16665769.)
Stroke, Cardiology General, Valvular Heart Disease, Cardiology, Neurology/Neurosurgery
2403-2412
Kharbanda, Rajesh K.
be90e317-2d2e-41bd-99aa-3d8c369a82ed
Kennedy, James
8c558484-4c17-463d-a749-0f0872de26d9
Jamal, Zahra
e53bf6f2-9064-4649-8348-16b6ffe93904
Curzen, Nick
70f3ea49-51b1-418f-8e56-8210aef1abf4
BHF PROTECT-TAVI Investigators
26 June 2025
Kharbanda, Rajesh K.
be90e317-2d2e-41bd-99aa-3d8c369a82ed
Kennedy, James
8c558484-4c17-463d-a749-0f0872de26d9
Jamal, Zahra
e53bf6f2-9064-4649-8348-16b6ffe93904
Curzen, Nick
70f3ea49-51b1-418f-8e56-8210aef1abf4
Kharbanda, Rajesh K., Kennedy, James and Jamal, Zahra
,
et al. and BHF PROTECT-TAVI Investigators
(2025)
Routine cerebral embolic protection during transcatheter aortic-valve implantation.
New England Journal of Medicine, 392 (24), .
(doi:10.1056/NEJMoa2415120).
Abstract
Background: transcatheter aortic-valve implantation (TAVI) is associated with procedure-related stroke. Cerebral embolic protection (CEP) devices may reduce embolization to the cerebral circulation and hence the incidence of stroke.
Methods: we conducted a randomized, controlled trial across 33 centers in the United Kingdom. We randomly assigned 7635 participants with aortic stenosis in a 1:1 ratio to undergo TAVI with a CEP device (CEP group) or TAVI without a CEP device (control group). The primary outcome was stroke within 72 hours after TAVI or before discharge from the hospital (if discharge occurred sooner).
Results: a total of 3815 participants were assigned to the CEP group and 3820 to the control group. A primary-outcome event occurred in 81 of 3795 participants (2.1%) in the CEP group and in 82 of 3799 participants (2.2%) in the control group (difference, −0.02 percentage points; 95% confidence interval, –0.68 to 0.63; P=0.94). Disabling stroke occurred in 47 participants (1.2%) in the CEP group and in 53 (1.4%) in the control group. Death occurred in 29 participants (0.8%) in the CEP group and in 26 (0.7%) in the control group. Overall access-site complications appeared to be similar in the two groups (8.1% in the CEP group and 7.7% in the control group). A total of 24 serious adverse events occurred in 22 of 3798 participants (0.6%) in the CEP group, and 13 serious adverse events occurred in 13 of 3803 participants (0.3%) in the control group.
Conclusions: among participants undergoing TAVI, routine use of CEP did not decrease the incidence of stroke within 72 hours. (Funded by the British Heart Foundation and Boston Scientific; BHF PROTECT-TAVI ISRCTN Registry number, ISRCTN16665769.)
Text
AAM_ NEJMoa2415120--manuscript
- Accepted Manuscript
More information
Accepted/In Press date: 13 March 2025
e-pub ahead of print date: 30 March 2025
Published date: 26 June 2025
Additional Information:
Kharbanda RK, Kennedy J, Jamal Z, Dodd M, Evans R, Bal KK, Perkins AD, Blackman DJ, Hildick-Smith D, Banning AP, Baumbach A, Ludman P, Palmer S, Stables RH, Henderson R, Appleby C, Cotton J, Curzen N, Ozkor M, Byrne J, Aggarwal R, Das R, Doshi S, Watkins S, Muir DF, Anderson R, Chowdhary S, Varcoe R, Dorman S, Firoozi S, Chelliah R, Owens C, Redwood S, Prendergast B, Iqbal J, Ratib K, Dospinescu C, Suresh V, Cruden N, Rajathurai T, Malik IS, Wiper A, Costopoulos C, Khurana A, Banning A, Clayton T; BHF PROTECT-TAVI Investigators.
Keywords:
Stroke, Cardiology General, Valvular Heart Disease, Cardiology, Neurology/Neurosurgery
Identifiers
Local EPrints ID: 501099
URI: http://eprints.soton.ac.uk/id/eprint/501099
ISSN: 0028-4793
PURE UUID: b784cff6-1cbe-4e0e-9aee-e15d9461c898
Catalogue record
Date deposited: 23 May 2025 16:49
Last modified: 11 Sep 2025 02:13
Export record
Altmetrics
Contributors
Author:
Rajesh K. Kharbanda
Author:
James Kennedy
Author:
Zahra Jamal
Corporate Author: et al.
Corporate Author: BHF PROTECT-TAVI Investigators
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
